Steven Cohen Mereo Biopharma Group PLC Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $4,370 - $7,695	1,900 New	1,900 $6,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.73 $169,425 - $357,445	-206,616 Reduced 2.06%	9,829,354 $8.46 Million
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $481,479 - $2.47 Million	-1,459,030 Reduced 12.69%	10,035,970 $11.2 Million
Q1 2022 May 16, 2022	BUY	$1.04 - $1.7 $920,400 - $1.5 Million	885,000 Added 8.34%	11,495,000 $12.9 Million
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.59 $958,850 - $1.64 Million	635,000 Added 6.37%	10,610,000 $17 Million
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $290,815 - $419,039	-132,189 Reduced 1.31%	9,975,000 $24.1 Million
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $5.38 Million - $7.47 Million	1,830,689 Added 22.12%	10,107,189 $32 Million
Q1 2021 May 17, 2021	BUY	$2.6 - $4.43 $21.5 Million - $36.7 Million	8,276,500 New	8,276,500 $27.9 Million
Q4 2020 Feb 16, 2021	SELL	$1.95 - $3.6 $554,714 - $1.02 Million	-284,469 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.55 - $3.29 $230,854 - $297,846	-90,531 Reduced 24.14%	284,469 $745,000
Q2 2020 Aug 14, 2020	BUY	$1.0 - $3.4 $375,000 - $1.28 Million	375,000 New	375,000 $1.15 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.